Muchun Li
Overview
Explore the profile of Muchun Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen H, Bai Z, Tao S, Li M, Jian L, Zhang Y, et al.
Int J Biol Macromol
. 2024 Jul;
276(Pt 2):133969.
PMID: 39029849
In this study, an enzyme-assisted microwave extraction process was obtained by response surface method of polysaccharide from roots of Rubus crataegifolius Bunge. The optimized extraction process was as follow: enzyme...
2.
Zhang X, Lao M, Yang H, Sun K, Dong Y, He L, et al.
Autophagy
. 2024 Jan;
20(6):1314-1334.
PMID: 38174993
Accumulating evidence suggests that cancer-associated fibroblast (CAF) macroautophagy/autophagy is crucial in tumor development and may be a therapeutic target for pancreatic ductal adenocarcinoma (PDAC). However, the role of CAF autophagy...
3.
Sun K, Zhang X, Lao M, He L, Wang S, Yang H, et al.
Mol Ther
. 2023 Jul;
31(10):2929-2947.
PMID: 37515321
Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to immune checkpoint blockade therapy, and negative feedback of tumor immune evasion might be partly responsible. We isolated CD8+ T cells and cultured...
4.
Duan Y, Zhang X, Ying H, Xu J, Yang H, Sun K, et al.
Oncogene
. 2023 May;
42(25):2061-2073.
PMID: 37156839
Highly desmoplastic and immunosuppressive tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) contributes to tumor progression and resistance to current therapies. Clues targeting the notorious stromal environment have offered hope...
5.
Yang H, Zhang X, Lao M, Sun K, He L, Xu J, et al.
Cell Death Differ
. 2022 Dec;
30(2):560-575.
PMID: 36539510
Programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) help tumor cells evade immune surveillance, and are regarded as important targets of anti-tumor immunotherapy. Post-translational modification of PD-L1 has...
6.
Chen W, Wen L, Bao Y, Tang Z, Zhao J, Zhang X, et al.
Proc Natl Acad Sci U S A
. 2022 Dec;
119(52):e2203894119.
PMID: 36534812
The gut microbiota and liver cancer have a complex interaction. However, the role of gut microbiome in liver tumor initiation remains unknown. Herein, liver cancer was induced using hydrodynamic transfection...
7.
Cao X, Li M, Ma L, Wang M, Hou X, Maiwulanjiang M
Molecules
. 2022 May;
27(9).
PMID: 35565985
The chromatographic fingerprint of 14 batches of L. samples were established in this study. The constituents of ten components in L. were determined using quantitative analysis of multi-components by single...
8.
Li M, Zhang X, Bai X, Liang T
Front Oncol
. 2022 May;
12:862154.
PMID: 35494080
Tumor necrosis factor (TNF) receptor type II (TNFR2) is expressed in various tumor cells and some immune cells, such as regulatory T cells and myeloid-derived suppressing cells. TNFR2 contributes a...
9.
Wang D, Yan F, Wu P, Ge K, Li M, Li T, et al.
Nat Commun
. 2022 Mar;
13(1):1369.
PMID: 35296687
Lysine benzoylation (Kbz) is a recently discovered post-translational modification associated with active transcription. However, the proteins for maintaining and interpreting Kbz and the physiological roles of Kbz remain elusive. Here,...
10.
Zhang X, Lao M, Xu J, Duan Y, Yang H, Li M, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35260434
Backgrounds: In advanced pancreatic ductal adenocarcinoma (PDAC), immune therapy, including immune checkpoint inhibitors, has limited efficacy, encouraging the study of combination therapy. Methods: Tumor necrosis factor receptor 2 (TNFR2) was...